Ensuring access to treatment for patients

Provide medicinal products derived from plasma and recombinant proteins, ensuring their availability while helping to improve patient care pathways thanks to LFB’s commitment to caregivers and patient associations.
Servirpatients Header

Serving patients: at the heart of LFB’s mission

In the face of rapidly increasing patient needs and strained production capacities, LFB has committed to ensuring equitable and safe access to treatments, both today and for future generations:

  • By tripling its production capacity for plasma-derived medicinal products,
  • By expanding its offerings with its own plasma collection centres,
  • By helping improve patient care pathways, facilitating access to information, and ensuring better treatment monitoring, thanks to its commitment to caregivers and patient associations.
Strategic pillar of our plasma collection network

Europlasma operates 26 centres in Austria, Germany, and the Czech Republic.

With LFB American Plasma in the United States, we also have plasma and blood collection centres to meet regulatory requirements. In accordance with US FDA requirements, only medicinal products derived from plasma donated in the USA can be sold in the USA.

LFB plasma collection

Our evidence:

  • DOING EVERYTHING WE CAN TO HONOR OUR COMMITMENTS AND PROVIDE OUR MEDICINAL PRODUCTS TO MARKET IN FRANCE AND INTERNATIONALLY: - Triple LFB’s fractionation capacity with full commissioning of the Arras plant. - Align our collection capacity with our fractionation capacity. - Support the EFS’s communications campaigns to increase plasma volumes collected in France. MAINTAINING THE QUALITY OF OUR PRODUCTS: - Double the number of production sites approved by international health authorities by 2030. - Improve 2030 to less than 2 major remarks observed during external audits (health regulatory authorities). INCREASING INTERACTIONS WITH PATIENT ASSOCIATIONS AND CONTRIBUTING TO IMPROVING CARE PATHWAYS: - Present all strategic product development projects to relevant patient associations by 2026. - Continue reliable involvement with patient associations through LFB’s commitment and forging of partnerships with patient associations. - Contribute to improving patient care pathways.

CONTEXT FOR UNDERSTANDING THE CHALLENGES

Ensuring access to treatment in the face of rapidly growing demand

Each year, the number of patients who need treatment with PDMPs increases and therefore demand for plasma-derived medicinal products continues to rise, which puts increased pressure on available volumes.
In this context, the French government has entrusted LFB with a public health mission: to provide medicinal products derived from plasma collected by the French Blood Establishment (EFS)* to market and give priority to patients in France.

To achieve its mission, the LFB relies on an exclusive partnership with the EFS that is in charge of collection in France, with the aim of ensuring France’s health sovereignty.
In 2024, public or private plasma collection structures will only be able to cover 74% of immunoglobulins needs worldwide*. This situation requires a collective strategy to secure access to treatment for patients. Patient associations and health systems alike contribute to improving access and continuity of treatment for patients.

*Article L5124-14 of the French Public Health Code modified in 2015 by Law No. 2015-990, article 190.

  • 300,000patients in Europe depend on Plasma-derived each day

  • 6 to 8%annual growth in the plasma-derived products market

  • Servirpatients Image2

Find out more about the other pillars of our CSR Strategy:

Sources: